Loading...
Loading...
Alkermes plc
today announced the presentation of positive phase
2 data for ALKS 5461, a novel opioid modulator, in patients with major
depressive disorder (MDD) and inadequate response to standard therapies. In
the phase 2 study, ALKS 5461 met its primary endpoint, met key secondary
endpoints and demonstrated significant reduction in depressive symptoms versus
placebo. The study is being presented in an oral session at the 53^rd Annual
New Clinical Drug Evaluation Unit (NCDEU) Meeting in Hollywood, Fla., by
Maurizio Fava, M.D., of Massachusetts General Hospital and Harvard Medical
School.
“The magnitude of effect seen with ALKS 5461 in this study is highly
significant. These results are very encouraging for ALKS 5461 as a potential
new treatment approach, with substantial reductions in depressive symptoms
demonstrated and rapid onset of action observed,” stated Maurizio Fava, M.D.,
Director of the Depression Clinical and Research Program at Massachusetts
General Hospital and Slater Family Professor of Psychiatry at Harvard Medical
School.
The phase 2 study of ALKS 5461 utilized a sequential parallel comparison
design (SPCD), designed to reduce the impact of clinically meaningful response
to treatment with placebo. The study included two four-week, randomized,
double-blind stages run in sequence: an Initial Study Stage and a Successive
Study Stage. The Successive Study Stage randomized only those patients who
were non-responders to placebo in the Initial Study Stage. Both stages of the
phase 2 study evaluated two doses of ALKS 5461, a lower dose and a higher
dose. Overall, the combined analysis of both doses at both stages showed
statistically significant efficacy on multiple endpoints compared to placebo.
Overall, the lower dose showed greater efficacy than the higher dose and, as a
result, will be the top end of the dose range employed in future studies.
Results for the lower dose from the Successive Study Stage of the study
included:
* ALKS 5461 significantly reduced Hamilton Depression Rating Scale (HAM-D17)
scores from baseline (p=0.013), with a reduction of 5.3 points, compared
to a reduction of 1.2 points in the placebo group at the end of the
four-week treatment period. ALKS 5461 also significantly reduced
Montgomery–Åsberg Depression Rating Scale (MADRS) scores from baseline
(p=0.004), with a reduction of 8.7 points, compared to a reduction of 1.8
points in the placebo group at the end of the four-week treatment period.
* ALKS 5461 had an onset of effect, as measured by MADRS, evident after one
week of treatment.
In the phase 2 results for the overall study population, including both the
Initial Study Stage and the Successive Study Stage, patients who received
either dose of ALKS 5461 for a treatment period of four weeks showed a
significant reduction in depressive symptoms from baseline in HAM-D17
(p=0.026) and MADRS (p=0.004) scores, compared to placebo. The primary
endpoint of the phase 2 study was the change from baseline in depressive
symptoms over a four-week treatment period in the overall study population, as
measured by HAM-D17, compared to placebo. Data from the study showed that ALKS
5461 was generally well tolerated. The most common adverse events observed in
the study were nausea, headache and dizziness.
“ALKS 5461 reflects a new approach to the treatment of major depressive
disorder based on modulation of the opioid system in the brain. With these
compelling data in hand, we are planning to meet with the U.S. FDA as we work
to advance ALKS 5461 to pivotal clinical development,” stated Elliot Ehrich,
M.D., Chief Medical Officer of Alkermes. “ALKS 5461, one of several product
candidates in our advancing clinical pipeline, is an excellent example of how
Alkermes is leveraging our unique understanding of opioid biology and
pharmacology to develop medications that address unmet medical needs for
central nervous system disorders.”
Study Design
This phase 2, randomized, double-blind, multicenter, placebo-controlled study
assessed the efficacy and safety of once-daily ALKS 5461 as adjunctive
treatment in 142 patients with MDD who had an inadequate response to a stable
dose of either a selective serotonin reuptake inhibitor (SSRI) or a
serotonin-norepinephrine reuptake inhibitor (SNRI). Two doses of ALKS 5461
were evaluated, each with a 1:1 ratio of buprenorphine and ALKS 33 (lower dose
of 2mg/2mg and higher dose of 8mg/8mg). The primary endpoint of the study was
the change from baseline in depressive symptoms over a four-week treatment
period, as measured by HAM-D17. Secondary endpoints included additional
analyses of patient responses based on HAM-D17, MADRS and Clinical Global
Impression – Severity Scale (CGI-S) scores.
The study utilized a sequential parallel comparison design (SPCD), a design
developed ten years ago by Drs. Fava and Schoenfeld at Massachusetts General
Hospital and now widely utilized in clinical trials. A SPCD trial involves two
randomized, double-blind stages run in sequence. In the Initial Study Stage
(stage 1), patients are randomized to either drug treatment or placebo. In the
ALKS 5461 phase 2 study, the Initial Study Stage was a four-week treatment
period. At the end of the Initial Study Stage, patients were reassigned
treatment groups for the Successive Study Stage (stage 2), which in the ALKS
5461 phase 2 study was a second four-week treatment period. In the Successive
Study Stage, patients who had been on drug in the Initial Study Stage were put
on placebo. Patients who had been administered placebo in the Initial Study
Stage were determined to be either responders, i.e., they responded positively
to placebo treatment, or non-responders. Placebo responders were assigned to
remain on placebo in the Successive Study Stage. Placebo non-responders were
re-randomized to either placebo or drug treatment in the Successive Study
Stage. SPCD studies are particularly useful in studies of depression, anxiety
and other difficult psychiatric diseases to reduce the impact of placebo
effect on the assessment of treatment response.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in